Proteins in a bio-chemical pathway, that play a key role in regulating blood pressure and flow have been identified by scientists.
The findings have evolved from studies conducted by Jeffrey S. Isenberg, Eileen M. Bauer, and their colleagues at the University of Pittsburgh School of Medicine.
Advertisement"Identifying and unravelling this important pathway for blood pressure regulation could lead to a better understanding of who will get high blood pressure and why, as well as allow us to develop better drugs to treat these patients," Isenberg said.
"Poorly controlled hypertension is a major risk factor for heart attacks and heart failure, stroke and kidney failure," he added.
Isenberg and collaborator David D. Roberts, of the National Cancer Institute, National Institutes of Health, have been exploring uses of nitric oxide signaling.
The cells that line blood vessels, called the endothelium, produce NO in a few biochemical steps. NO promotes blood vessel dilation and increases blood flow. Conversely, endothelial dysfunction, along with loss of NO production, is known to be involved in the development of many forms of cardiovascular disease, including hypertension.
Through cell culture and mouse experiments, the researchers found that a protein called thrombospondin-1 (TSP1) and its receptor, CD47, inhibit activation of the endothelial-based enzyme called endothelial nitric oxide synthase (eNOS), which in turn limits the production of NO and thus prevents blood vessels from relaxing and blood pressure from dropping. Circulating TSP1, at levels consistent with those found in the blood stream, is capable of inhibiting activation of endothelial-based eNOS and thus blocking NO production.
"For some time now, it has not been clear what role TSP1 served in the blood. Experiments in cells told us TSP1 could alter NO signaling. But TSP1 is a protein too large to cross through the endothelial layer and into the blood vessel wall, so it was not obvious how it could alter the muscle tone of the arteries," Isenberg said.
"We also knew that mice genetically engineered to not produce TSP1 or CD47 showed more NO-based blood flow and blood vessel dilation. This suggested to us that perhaps circulating TSP1 was altering the ability of the endothelium to make NO by acting on eNOS," he added.
The findings have been published in the early online version of Cardiovascular Research.